Primary Lateral Sclerosis (Pls) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Primary lateral sclerosis (PLS) is a rare, adult-onset neurodegenerative disorder characterized by progressive spasticity and upper motor neuron (UMN) dysfunction due to selective degeneration of the corticospinal tracts. PLS is classified among the [motor neuron diseases] but is distinguished from [amyotrophic lateral sclerosis (ALS)[/diseases/[als[/diseases/[als[/diseases/[als[/diseases/[als--TEMP--/diseases)--FIX-- by the absence of significant lower motor neuron (LMN) involvement and its substantially slower progression (Gordon et al., 2006). With an estimated prevalence of 1–2 per million, PLS accounts for approximately 2–4% of all [Motor Neuron Disease[/diseases/[motor-neuron-disease[/diseases/[motor-neuron-disease[/diseases/[motor-neuron-disease[/diseases/[motor-neuron-disease--TEMP--/diseases)--FIX-- cases.
The hallmark of PLS is progressive spasticity beginning in the lower limbs, ascending over years to involve the upper limbs and bulbar muscles. Patients develop stiff, clumsy gait, hyperreflexia, and eventually speech and swallowing difficulties. Unlike ALS, most PLS patients survive 10–20+ years from onset and often die from unrelated causes. The 2020 international consensus diagnostic criteria formalized the clinical and electrophysiological requirements for diagnosis, requiring at least 2 years of progressive UMN dysfunction without LMN involvement (Turner et al., 2020).
- Prevalence: Approximately 1–2 per million; rarer than ALS (5–7 per 100,000)
- Age of onset: Typically 40–60 years (mean ~50 years); rare before age 40
- Sex distribution: Slight male predominance (~1.5:1 M:F)
- Genetic: The vast majority of PLS cases are sporadic. Rare familial cases have been linked to mutations in ALS2 (alsin) causing a juvenile-onset recessive form
¶ Classification and Relationship to ALS
PLS exists on a spectrum with other UMN disorders:
- Definite PLS: Progressive UMN dysfunction for ≥4 years without EMG evidence of active denervation
- Probable PLS: Progressive UMN dysfunction for 2–4 years with supportive features
- PLS-plus/PLS converting to ALS: 10–30% of patients initially diagnosed with PLS develop LMN signs within the first 4 years, reclassifying them as UMN-predominant ALS. This conversion risk decreases significantly after 4 years of pure UMN disease
- Hereditary spastic paraplegia (HSP): Must be excluded through [genetic testing[/diagnostics/[genetic-testing[/diagnostics/[genetic-testing[/diagnostics/[genetic-testing[/diagnostics/[genetic-testing--TEMP--/diagnostics)--FIX--, especially in patients with positive family history or onset before age 40
The 2020 consensus criteria addressed the diagnostic challenge by defining time thresholds: probable PLS requires ≥2 years of symptoms, definite PLS requires ≥4 years (Turner et al., 2020). A 2024 validation study found that at baseline assessment, 28% met definite criteria, 19% met probable criteria, and 53% did not initially meet full criteria — highlighting the diagnostic challenge (Mitsumoto et al., 2024).
PLS is characterized by selective degeneration of the corticospinal motor [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- in the primary motor [cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex--TEMP--/brain-regions)--FIX-- (Betz cells) and their axonal projections through the corticospinal tracts:
- Betz cell loss: Loss of the giant pyramidal [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- in layer 5 of the primary motor [cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex--TEMP--/brain-regions)--FIX--
- Corticospinal tract degeneration: Myelin pallor and axonal loss in the lateral columns of the [spinal cord[/brain-regions/[spinal-cord[/brain-regions/[spinal-cord[/brain-regions/[spinal-cord[/brain-regions/[spinal-cord--TEMP--/brain-regions)--FIX--
- Minimal LMN pathology: Anterior horn cells are relatively preserved, distinguishing PLS from ALS neuropathologically
The pathophysiology of PLS remains incompletely understood but likely involves:
- [excitotoxicity[/entities/[excitotoxicity[/entities/[excitotoxicity[/entities/[excitotoxicity[/entities/[excitotoxicity--TEMP--/entities)--FIX--: [glutamate[/entities/[glutamate[/entities/[glutamate[/entities/[glutamate[/entities/[glutamate--TEMP--/entities)--FIX---mediated excitotoxic damage to corticospinal motor [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX--, similar to ALS
- Protein aggregation: [TDP-43[/entities/[tdp-43[/entities/[tdp-43[/entities/[tdp-43[/entities/[tdp-43--TEMP--/entities)--FIX-- pathology has been identified in some PLS cases at autopsy, suggesting shared proteinopathy with ALS and [FTD[/diseases/[ftd[/diseases/[ftd[/diseases/[ftd[/diseases/[ftd--TEMP--/diseases)--FIX--
- [neuroinflammation[/mechanisms/[neuroinflammation[/mechanisms/[neuroinflammation[/mechanisms/[neuroinflammation[/mechanisms/[neuroinflammation--TEMP--/mechanisms)--FIX--: Microglial activation along the corticospinal tracts
- Cortical hyperexcitability: Transcranial magnetic stimulation (TMS) studies show loss of cortical inhibition and increased motor [cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex--TEMP--/brain-regions)--FIX-- excitability early in disease
PLS typically presents insidiously with lower limb stiffness and spasticity, ascending over years:
- Lower limb onset (most common): Stiff, spastic gait; difficulty with balance, stairs, and turning; frequent tripping. Legs feel "heavy" or "wooden"
- Spasticity: Velocity-dependent increase in muscle tone, often severe; painful spasms
- Hyperreflexia: Pathologically brisk deep tendon reflexes with clonus
- Babinski sign: Extensor plantar responses bilaterally
- Pseudobulbar affect: Involuntary laughing/crying due to bilateral corticobulbar tract involvement
Bulbar onset occurs in approximately 25% of cases:
- Spastic dysarthria: Slow, effortful, strained-strangled speech quality
- Dysphagia: Difficulty swallowing due to spastic pharyngeal muscles; aspiration risk
- Emotional lability: Pseudobulbar affect with pathological laughing/crying
- Jaw clonus: Exaggerated jaw jerk reflex
| Feature |
PLS |
ALS |
| Motor neuron involvement |
UMN only |
UMN + LMN |
| Fasciculations |
Absent/rare |
Prominent |
| Muscle atrophy |
Minimal |
Prominent |
| Progression rate |
Slow (years–decades) |
Rapid (2–5 years) |
| Median survival |
10–20+ years |
3–5 years |
| EMG findings |
No active denervation |
Active denervation |
| Respiratory failure |
[Late[/diseases/[late[/diseases/[late[/diseases/[late[/diseases/[late--TEMP--/diseases)--FIX--/rare |
Common cause of death |
The international consensus criteria require (Turner et al., 2020):
- Progressive UMN dysfunction in ≥2 body regions (limbs, bulbar, trunk)
- Duration ≥2 years from symptom onset (probable PLS) or ≥4 years (definite PLS)
- Absence of active LMN signs on clinical exam and EMG
- Exclusion of structural, metabolic, inflammatory, and genetic mimics
- Electromyography (EMG): Must show no evidence of active denervation (fibrillation potentials, positive sharp waves). Mild chronic neurogenic changes may be acceptable if limited
- MRI brain and spinal cord: Rule out structural lesions; may show motor [cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex--TEMP--/brain-regions)--FIX-- atrophy, T2 hyperintensity along corticospinal tracts
- Genetic testing: Exclude HSP panel, ALS2 mutations, and other genetic mimics
- Blood work: Exclude vitamin B12 deficiency, copper deficiency, HTLV-1/2, syphilis, HIV
- CSF: If inflammatory myelopathy is suspected; may show mildly elevated [NfL[/entities/[neurofilament-light[/entities/[neurofilament-light[/entities/[neurofilament-light[/entities/[neurofilament-light--TEMP--/entities)--FIX--
- TMS: May reveal prolonged central motor conduction time and absent motor-evoked potentials
- [Neurofilament light chain (NfL)[/proteins/[nfl-protein[/proteins/[nfl-protein[/proteins/[nfl-protein[/proteins/[nfl-protein--TEMP--/proteins)--FIX--: Elevated in PLS but typically lower than in ALS, potentially helping distinguish the two
- TMS metrics: Cortical silent period and intracortical inhibition measures may serve as monitoring biomarkers
No disease-modifying therapy is approved for PLS. Management is multidisciplinary and symptomatic:
- Baclofen: First-line oral antispasticity agent; intrathecal baclofen pump for severe refractory spasticity
- Tizanidine: Alpha-2 adrenergic agonist; alternative to baclofen
- Botulinum toxin: Targeted injection for focal spasticity
- Physical therapy: Regular stretching, range-of-motion exercises, and gait training are essential; aquatic therapy may be particularly beneficial
- Speech therapy: Communication strategies, augmentative/alternative communication devices
- Swallowing evaluation: Modified barium swallow to assess aspiration risk; dietary modifications
- PEG tube: For nutritional support if swallowing becomes unsafe
- Pseudobulbar affect: Dextromethorphan/quinidine (Nuedexta) or SSRIs for involuntary laughing/crying
- Assistive devices: Ankle-foot orthoses (AFOs), walkers, wheelchairs as disease progresses
- [Home[/[home[/[home[/[home[/[home[/[home[/[home[/[home[/home modifications: Grab bars, stair lifts, accessible bathroom equipment
PLS has a significantly better prognosis than ALS:
- Median survival: 10–20+ years from symptom onset; many patients survive >20 years
- Ambulatory function: Most patients require assistive devices within 5–10 years; wheelchair use typically occurs late
- Conversion to ALS: 10–30% of patients develop LMN signs within the first 4 years, converting to a diagnosis of UMN-predominant ALS with worse prognosis
- Cause of death: Often unrelated to PLS; aspiration pneumonia is the most common disease-related complication
- Biomarker development: [NfL[/entities/[neurofilament-light[/entities/[neurofilament-light[/entities/[neurofilament-light[/entities/[neurofilament-light--TEMP--/entities)--FIX-- and TMS-based biomarkers for early diagnosis, prognostication, and trial readiness
- Genetic studies: Whole genome sequencing to identify genetic risk factors for sporadic PLS
- Neuroprotective trials: Repurposing ALS drugs (e.g., [edaravone[/treatments/[edaravone[/treatments/[edaravone[/treatments/[edaravone[/treatments/[edaravone--TEMP--/treatments)--FIX--, [tofersen[/treatments/[tofersen[/treatments/[tofersen[/treatments/[tofersen[/treatments/[tofersen--TEMP--/treatments)--FIX-- approaches) for PLS
- Natural history studies: Prospective registries to characterize PLS progression and phenotypic variability
- [All Diseases[/[diseases[/[diseases[/[diseases[/[diseases[/[diseases[/[diseases[/[diseases[/diseases
The study of Primary Lateral Sclerosis (Pls) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying [mechanisms of neurodegeneration[/[mechanisms[/[mechanisms[/[mechanisms[/[mechanisms[/[mechanisms[/[mechanisms[/[mechanisms[/mechanisms and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- [Gordon PH, Cheng B, Katz IB, et al. The natural history of primary lateral sclerosis. Neurology. 2006;66(5):647-653. [doi:10.1212/01.wnl.0000200962.94777.71]https://pubmed.ncbi.nlm.nih.gov/16648143/)
- [Turner MR, Barohn RJ, Corcia P, et al. Primary lateral sclerosis: consensus diagnostic criteria. J Neurol Neurosurg Psychiatry. 2020;91(4):373-377. [doi:10.1136/jnnp-2019-322541]https://pubmed.ncbi.nlm.nih.gov/32029539/)
- [Mitsumoto H, Factor-Litvak P, et al. Primary lateral sclerosis: application and validation of the 2020 consensus diagnostic criteria. Amyotroph Lateral Scler Frontotemporal Degener. 2024;25(3-4]:303-312. [doi:10.1080/21678421.2024.2313427]https://pubmed.ncbi.nlm.nih.gov/38388486/)
- [Statland JM, Barohn RJ, Dimachkie MM, et al. Primary lateral sclerosis. Neurol Clin. 2015;33(4):749-760. [doi:10.1016/j.ncl.2015.07.007]https://pubmed.ncbi.nlm.nih.gov/26515619/)
- [Tartaglia MC, Rowe A, Bhatt K, et al. Differentiation between primary lateral sclerosis and amyotrophic lateral sclerosis: examination of symptoms and signs at disease onset and during follow-up. Arch Neurol. 2007;64(2):232-236. [doi:10.1001/archneur.64.2.232]https://pubmed.ncbi.nlm.nih.gov/17296839/)
- [Le Forestier N, Maisonobe T, Piquard A, et al. Does primary lateral sclerosis exist? A study of 20 patients and a review of the literature. Brain. 2001;124(10):1989-1999. [doi:10.1093/brain/124.10.1989]https://pubmed.ncbi.nlm.nih.gov/11571217/)
- [Finegan E, Chipika RH, Shing SLH, et al. Primary lateral sclerosis: a distinct entity or part of the ALS spectrum? Amyotroph Lateral Scler Frontotemporal Degener. 2019;20(3-4]:133-145. [doi:10.1080/21678421.2018.1550518]https://pubmed.ncbi.nlm.nih.gov/30596308/)
- [D'Amico E, Grosso G, Factor-Litvak P, et al. Primary lateral sclerosis: an overview. J Clin Med. 2024;13(2):578. [doi:10.3390/jcm13020578]https://pmc.ncbi.nlm.nih.gov/articles/PMC10816328/)
- [Singer MA, Statland JM, Wolfe GI, Barohn RJ. Primary lateral sclerosis. Muscle Nerve. 2007;35(3):291-302. [doi:10.1002/mus.20728]https://pubmed.ncbi.nlm.nih.gov/17143894/)
- [Mitsumoto H. Primary lateral sclerosis: more than just an upper Motor [Neuron[/entities/[neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- Disease. Neural Regen Res. 2024;19(9):1879-1880. [doi:10.4103/NRR.NRR-D-24-00296]https://journals.lww.com/nrronline/fulltext/2024/09000/primary_lateral_sclerosis__more_than_just_an_upper.11.aspx)